Noxopharm Limited is an innovative Australian biotech company specializing in the discovery and development of novel treatments for cancer and inflammation, as well as improving mRNA vaccines. As a publicly-listed clinical stage drug development company, Noxopharm has three active drug development programs that focus on two innovative technology platforms: Sofra™, which is dedicated to mRNA vaccines, inflammation, and autoimmunity, and Chroma™, which focuses on oncology. These platforms provide the foundation for a growing pipeline of proprietary drugs.

The company's lead clinical drug candidate, Veyonda®, is a first-in-class, dual-acting cytotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. Noxopharm also holds a significant shareholding in the US biotech company Nyrada Inc, which is actively involved in drug development for cardiovascular and neurological diseases. With a commitment to advancing medical research, Noxopharm aims to revolutionize cancer treatment and improve patient outcomes.

Please note that Veyonda® is currently not approved in Australia or any other country